Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
Achievement of glycemic control is the major therapeutic aim to prevent or delay the onset and progression of diabetes related complications. Insulin therapy represents a cornerstone in the treatment of diabetes and has been used widely for achieving glycemic goals. The aim for insulin therapy is to...
Main Authors: | Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova |
---|---|
Format: | Article |
Language: | English |
Published: |
Endocrinology Research Centre
2014-12-01
|
Series: | Сахарный диабет |
Subjects: | |
Online Access: | https://dia-endojournals.ru/dia/article/viewFile/6851/4787 |
Similar Items
-
Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
by: Sanjay Kalra
Published: (2016-01-01) -
Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
by: Shinje Moon, et al.
Published: (2021-09-01) -
Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
by: Sanjay Kalra, et al.
Published: (2016-01-01) -
Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014-06-01) -
Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
by: Kyu Yong Cho, et al.
Published: (2020-08-01)